RT Journal Article
SR Electronic
T1 Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 40
OP 47
VO 74
A1 Charles A Dinarello
YR 2005
UL http://www.jrheum.org/content/74/40.abstract
AB This review examines the differences in the incidence, spectrum, and mechanisms of activation of opportunistic infections, such as Mycobacterium tuberculosis, in patients with rheumatic diseases treated with the soluble TNF p75 receptor etanercept compared to the 2 anti-TNF-alpha monoclonal antibodies, infliximab and adalimumab.